Elevar Therapeutics: Clinical Trials

11 trials sponsored by Elevar Therapeutics, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 4 terminated, 1 recruiting, 1 withdrawn. 7 Phase 1, 6 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 17Completed 4, Terminated 3
Phase 26Completed 2, Terminated 2, Recruiting 1, Withdrawn 1
Phase 31Completed 1

Follow Elevar Therapeutics: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Lirafugratinib - FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Phase 2RecruitingElevar Therapeutics302026-06-042026-11-09
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
Rivoceranib - Metastatic Olfactory Neuroblastoma, Recurrent Olfactory Neuroblastoma
Phase 2WithdrawnM.D. Anderson Cancer Center2024-11-012025-01-10
A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants
Rivoceranib - Healthy
Phase 1CompletedElevar Therapeutics602021-12-302022-04-18
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
RLY-4008 - FGFR2 Amplification, FGFR2 Gene Mutation
Phase 1 / Phase 2CompletedElevar Therapeutics4902020-09-022026-02-27
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Rivoceranib - Adenoid Cystic Carcinoma
Phase 2TerminatedElevar Therapeutics802020-01-222026-07-30
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
Rivoceranib, Trifluridine/Tipiracil - Metastatic Colorectal Cancer
Phase 1TerminatedElevar Therapeutics292019-11-182024-05-02
A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
Rivoceranib, Paclitaxel - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Phase 1 / Phase 2TerminatedElevar Therapeutics122018-10-012022-04-11
Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
Apatinib, Pembrolizumab - Advanced Malignancies, Urothelial Carcinoma
Phase 1TerminatedUniversity of Utah52018-06-192020-07-15
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Apatinib, Nivolumab - Cancer
Phase 1CompletedElevar Therapeutics302017-12-222023-04-07
A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
Rivoceranib, Placebo - Gastric Cancer, Gastric Adenocarcinoma
Phase 3CompletedElevar Therapeutics4602017-03-142022-07-08
Dose-Escalation and Safety Trial of YN968D1
YN968D1 - Cancer Patients With Solid Tumors
Phase 1 / Phase 2CompletedElevar Therapeutics552012-04-012017-10-02

Conditions studied

Neoplasms (3)  ·  Neoplasm Metastasis (2)  ·  Stomach Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Carcinoma, Adenoid Cystic (1)  ·  Carcinoma, Transitional Cell (1)  ·  Cholangiocarcinoma (1)  ·  Colorectal Neoplasms (1)  ·  Esthesioneuroblastoma, Olfactory (1)

Interventions

apatinib (9)  ·  Nivolumab (1)  ·  Paclitaxel (1)  ·  pembrolizumab (1)  ·  trifluridine tipiracil drug combination (1)

Countries

United States (9)  ·  South Korea (6)  ·  France (3)  ·  United Kingdom (3)  ·  Germany (2)  ·  Italy (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Australia (1)  ·  Hong Kong (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Romania (1)  ·  Russia (1)

Top investigators

Luana Guimaraes De Sousa, MD (1)  ·  Min-Hee Ryu, Dr. (1)  ·  Sunil Sharma, MD, FACP (1)  ·  Yoon-Koo Kang, MD, PhD (1)

Results publications

PMID 36797744, PMID 38271925, PMID 41571046